<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30180594</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>01</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1543-8392</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>15</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>Molecular pharmaceutics</Title>                <ISOAbbreviation>Mol. Pharm.</ISOAbbreviation>            </Journal>            <ArticleTitle>A Novel Estrogen Receptor α-Targeted Near-Infrared Fluorescent Probe for in Vivo Detection of Breast Tumor.</ArticleTitle>            <Pagination>                <MedlinePgn>4702-4709</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.molpharmaceut.8b00684</ELocationID>            <Abstract>                <AbstractText>The ability to detect breast cancer early in its progression is essential to improve patient survival and quality of life. The noninvasive and dynamic imaging and functional assessments of estrogen receptor-alpha (ERα), which is commonly expressed at high levels in breast cancer, are important for effective diagnosis and treatment. Hence, the development of a specific ERα-targeted probe is a major research goal. To that end, in the present study, we created a novel near-infrared (NIR) fluorescent probe, IRDye800CW-E<sub>2</sub>, for targeted ERα imaging in breast-tumor-bearing mice. IRDye800CW-E<sub>2</sub> consisted of a cyanine dye IRDye800CW as the NIR fluorophore and the E<sub>2</sub> analogue ethinyl estradiol amine as an ERα targeting ligand. The ethinyl estradiol amine was initially labeled with fluorescein isothiocyanate (FITC) to evaluate the binding specificity to human breast-tumor cells in vitro. Flow chamber and in vitro confocal laser endomicroscopy imaging experiments demonstrated that FITC-E<sub>2</sub> was specifically taken up by MCF-7 cells. Furthermore, NIR fluorescence imaging revealed the ability of IRDye800CW-E<sub>2</sub> to rapidly target tumors and to achieve good contrast between tumors and background signal 4-48 h postinjection. The fluorescent signal of IRDye800CW-E<sub>2</sub> in tumors was successfully blocked by the coinjection of the endogenous ERα-ligand 17β-estradiol (E<sub>2</sub>) and the probe. Ex vivo fluorescent imaging further confirmed high uptake of the probe by tumors. These results indicated that IRDye800CW-E<sub>2</sub> has great potential as an ERα-targeted imaging probe for early breast-tumor detection and has potential for clinical translation.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Tang</LastName>                    <ForeName>Chu</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, School of Life Science and Technology , Xidian University , Xi'an , Shaanxi 710126 , China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation , Chinese Academy of Sciences , Beijing 100190 , China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Du</LastName>                    <ForeName>Yang</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation , Chinese Academy of Sciences , Beijing 100190 , China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Beijing Key Laboratory of Molecular Imaging , Beijing 100190 , China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>University of Chinese Academy of Sciences , Beijing 100080 , China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liang</LastName>                    <ForeName>Qian</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation , Chinese Academy of Sciences , Beijing 100190 , China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cheng</LastName>                    <ForeName>Zhen</ForeName>                    <Initials>Z</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8177-9463</Identifier>                    <AffiliationInfo>                        <Affiliation>Molecular Imaging Program at Stanford (MIPS), Department of Radiology, and Bio-X Program, Canary Center at Stanford for Cancer Early Detection , Stanford University , Stanford , California 94305-5344 , United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tian</LastName>                    <ForeName>Jie</ForeName>                    <Initials>J</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-9523-2271</Identifier>                    <AffiliationInfo>                        <Affiliation>Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, School of Life Science and Technology , Xidian University , Xi'an , Shaanxi 710126 , China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation , Chinese Academy of Sciences , Beijing 100190 , China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Beijing Key Laboratory of Molecular Imaging , Beijing 100190 , China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>University of Chinese Academy of Sciences , Beijing 100080 , China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>14</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Mol Pharm</MedlineTA>            <NlmUniqueID>101197791</NlmUniqueID>            <ISSNLinking>1543-8384</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">ERα-targeted imaging</Keyword>            <Keyword MajorTopicYN="N">NIR fluorescent probe</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">in vivo detection</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30180594</ArticleId>            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.8b00684</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>